Dr. Debu Tripathy from USC Norris Comprehensive Cancer Center on Breast Cancer with Bone Metastases
Debu Tripathy, MD, professor of medicine and co-leader of the Women's Cancer Program at the University of Southern California Norris Comprehensive Cancer Center, discusses the options available for breast cancer patients with bone metastases at the 28th Annual Miami Breast Cancer Conference.
Tripathy explains that bisphosphonates have been approved to lower skeletal-related events (SREs). These agents are becoming more commonly used. An exciting new agent is denosumab (Xgeva); Tripathy explains that this drug has shown more benefits and advantages, compared to other approved drugs, for the treatment of SREs.